Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,092 | 370 | 39.8% |
| Consulting Fee | $7,500 | 2 | 36.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $4,400 | 3 | 21.6% |
| Travel and Lodging | $342.25 | 4 | 1.7% |
| Education | $7.86 | 1 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| PFIZER INC. | $13,116 | 30 | $0 (2024) |
| ABBVIE INC. | $1,673 | 115 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $718.59 | 49 | $0 (2024) |
| Janssen Biotech, Inc. | $530.03 | 18 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $440.77 | 4 | $0 (2022) |
| Gilead Sciences, Inc. | $411.89 | 15 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $345.14 | 17 | $0 (2024) |
| Phathom Pharmaceuticals, Inc. | $277.47 | 6 | $0 (2024) |
| Celgene Corporation | $251.53 | 28 | $0 (2024) |
| Ardelyx, Inc. | $248.63 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $2,436 | 115 | ABBVIE INC. ($630.29) |
| 2023 | $1,568 | 99 | AbbVie Inc. ($416.38) |
| 2022 | $1,091 | 44 | ABBVIE INC. ($459.13) |
| 2021 | $618.91 | 23 | Janssen Biotech, Inc. ($124.79) |
| 2020 | $191.62 | 18 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($117.49) |
| 2019 | $8,529 | 29 | PFIZER INC. ($8,221) |
| 2018 | $5,403 | 27 | PFIZER INC. ($4,726) |
| 2017 | $504.18 | 25 | Janssen Scientific Affairs, LLC ($105.30) |
All Payment Transactions
380 individual payment records from CMS Open Payments — Page 1 of 16
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $23.22 | General |
| Category: Gastroenterology | ||||||
| 12/16/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $35.37 | General |
| Category: THERAPY FOR CSID | ||||||
| 12/12/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.97 | General |
| 12/06/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $13.00 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/05/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $25.11 | General |
| Category: IMMUNOLOGY | ||||||
| 12/02/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.03 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.52 | General |
| Category: Gastroenterology | ||||||
| 11/25/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $9.72 | General |
| Category: Immunology | ||||||
| 11/21/2024 | ABBVIE INC. | SKYRIZI (Biological) | Food and Beverage | In-kind items and services | $105.78 | General |
| Category: IMMUNOLOGY | ||||||
| 11/21/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $39.20 | General |
| Category: LIVER DISEASE | ||||||
| 11/20/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $39.19 | General |
| Category: THERAPY FOR CSID | ||||||
| 11/18/2024 | PFIZER INC. | XELJANZ (Drug), VELSIPITY | Food and Beverage | In-kind items and services | $28.74 | General |
| Category: GASTROINTESTINAL;INFLAMMATION;OPHTHALMOLOGY;TRANSPLANT | ||||||
| 11/16/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $217.89 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $14.21 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | SKYRIZI (Biological), RINVOQ | Food and Beverage | In-kind items and services | $3.02 | General |
| Category: IMMUNOLOGY | ||||||
| 11/14/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $0.75 | General |
| Category: IMMUNOLOGY | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug), STELARA | Food and Beverage | In-kind items and services | $138.60 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $43.02 | General |
| Category: Immunology | ||||||
| 11/13/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.33 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/08/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $21.61 | General |
| 11/07/2024 | Lilly USA, LLC | OMVOH (Drug) | Food and Beverage | In-kind items and services | $17.61 | General |
| Category: Immunology | ||||||
| 11/05/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $74.97 | General |
| Category: Immunology | ||||||
| 10/31/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: Immunology | ||||||
| 10/28/2024 | QOL Medical, LLC | SUCRAID (Drug) | Food and Beverage | Cash or cash equivalent | $27.50 | General |
| Category: THERAPY FOR CSID | ||||||
| 10/23/2024 | ABBVIE INC. | LINZESS (Drug), CREON | Food and Beverage | In-kind items and services | $10.80 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 423 | 478 | $351,574 | $53,559 |
| 2022 | 10 | 582 | 646 | $382,583 | $65,127 |
| 2021 | 11 | 587 | 667 | $379,530 | $69,279 |
| 2020 | 9 | 585 | 666 | $202,768 | $60,174 |
All Medicare Procedures & Services
39 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 105 | 148 | $51,504 | $13,331 | 25.9% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 52 | 53 | $75,578 | $11,193 | 14.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 32 | 32 | $35,072 | $5,864 | 16.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 68 | 79 | $18,723 | $4,782 | 25.5% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 55 | 55 | $63,962 | $4,605 | 7.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 37 | 37 | $20,054 | $4,267 | 21.3% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 38 | 38 | $56,843 | $4,229 | 7.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 23 | 23 | $25,184 | $4,153 | 16.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 13 | 13 | $4,654 | $1,135 | 24.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 171 | 227 | $78,996 | $20,388 | 25.8% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 47 | 47 | $67,022 | $9,639 | 14.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 113 | 121 | $28,677 | $7,239 | 25.2% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 32 | 32 | $33,856 | $6,032 | 17.8% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 39 | 39 | $52,377 | $5,400 | 10.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 42 | 42 | $22,764 | $5,227 | 23.0% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 55 | 55 | $61,820 | $4,533 | 7.3% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 54 | 54 | $19,332 | $3,558 | 18.4% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 13 | 13 | $13,819 | $2,385 | 17.3% |
| 99202 | New patient office or other outpatient visit, 15-29 minutes | Office | 2022 | 16 | 16 | $3,920 | $723.19 | 18.4% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 136 | 194 | $67,512 | $18,989 | 28.1% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 123 | 141 | $33,417 | $9,402 | 28.1% |
| 45385 | Removal of polyps or growths in large bowel using an endoscope (colonoscopy) using a mechanical snare | Facility | 2021 | 42 | 42 | $59,892 | $8,636 | 14.4% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 72 | 72 | $39,024 | $8,502 | 21.8% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2021 | 31 | 31 | $32,798 | $5,841 | 17.8% |
| 45380 | Biopsy of the large bowel using an endoscope (colonoscopy) | Facility | 2021 | 32 | 32 | $42,976 | $4,690 | 10.9% |
About Dr. Michael Brown, M.D
Dr. Michael Brown, M.D is a Gastroenterology healthcare provider based in Woodbridge, Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/27/2005. The National Provider Identifier (NPI) number assigned to this provider is 1861488637.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Brown, M.D has received a total of $20,342 in payments from pharmaceutical and medical device companies, with $2,436 received in 2024. These payments were reported across 380 transactions from 40 companies. The most common payment nature is "Food and Beverage" ($8,092).
As a Medicare-enrolled provider, Brown has provided services to 2,177 Medicare beneficiaries, totaling 2,457 services with total Medicare billing of $248,139. Data is available for 4 years (2020–2023), covering 39 distinct procedure/service records.
Practice Information
- Specialty Gastroenterology
- Location Woodbridge, VA
- Active Since 09/27/2005
- Last Updated 02/13/2018
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1861488637
Products in Payments
- XELJANZ (Drug) $13,050
- RINVOQ (Biological) $681.47
- STELARA (Biological) $671.38
- XIFAXAN (Drug) $425.56
- DUPIXENT (Biological) $411.37
- ZEPOSIA (Drug) $360.62
- SKYRIZI (Biological) $359.29
- VOQUEZNA (Drug) $277.47
- TREMFYA (Drug) $256.59
- IBSRELA (Drug) $248.63
- ENTYVIO (Biological) $190.79
- TRULANCE (Drug) $188.04
- GI GENIUS (Device) $176.15
- VIBERZI (Drug) $170.07
- CREON (Drug) $152.79
- OMVOH (Drug) $149.52
- DIFICID (Drug) $145.77
- LINZESS (Drug) $144.33
- SUCRAID (Drug) $126.81
- Epclusa (Drug) $111.60
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gastroenterology Doctors in Woodbridge
Dr. Kenneth Josovitz, M.d, M.D
Gastroenterology — Payments: $112,728
Dr. Jack Huang, M.d, M.D
Gastroenterology — Payments: $73,321
Dr. Atul Marathe
Gastroenterology — Payments: $10,207
Ali Kazemi, M.d, M.D
Gastroenterology — Payments: $9,618
Mohammad Razavi, Md, MD
Gastroenterology — Payments: $7,205
Anisha Thadani, Md, MD
Gastroenterology — Payments: $5,292